Volver a la clasificación

Tenet Healthcare Corp (THC)

Infravalorada
HealthcareMedical Care FacilitiesUnited States

Fundamental

69

Precio

$255.56

Capitalización Bursátil

$20.77B

Parte 1 · Cuánto vale la empresa

Resumen

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; pediatric quaternary care services through heart, liver, and kidney transplants programs; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging technology, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services comprising orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. Further, the company operates acute care and specialty hospitals, off-campus emergency departments, imaging centers, urgent care centers, and micro-hospitals, as well as ambulatory surgery centers and surgical hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$21.81B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$3.17B

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

$2.53B

Patrimonio Neto Total

$4.22B

Pasivo Total

$20.70B

Ratio de Liquidez

1.41

Cobertura de Intereses

5.54

Deuda/EBITDA

3.03

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Caso generalInfravalorado

Valor Justo

$610.78

Precio Actual

$255.56

Margen de Seguridad

+58.2%

Rango de Valor Justo

$397.01 - $824.55

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$284.64
Flujo de caja descontado (DCF):$1054.22
Múltiplo sobre beneficios (P/E):$314.40
Fórmula de crecimiento de Graham:$1331.27
Valor de la capacidad de generar beneficios (EPV):$380.62
P/B justificado:$268.25
Descuento de dividendos (Gordon):Datos insuficientes para calcularlo
P/FFO, fondos de operaciones:$641.84
Beneficios de mitad de ciclo:$625.19
Múltiplo sobre ingresos:$1042.88
Consenso de Analistas:Compra Fuerte (23B / 4H / 0S)
Última Sorpresa de Resultados:+43.62%

Métricas de Valoración

Ratio P/E

9.86

ROE

56.1%

Ratio P/B

4.42

P/FCF

6.81

Margen Bruto

-

ROIC

14.3%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

14.3%

WACC

8.8%

ROIC − WACC

+5.5 pp

El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.

Criterios de Análisis Fundamental

Superado (18)

  • EPS shows upward trend
  • EPS CAGR 40.13%
  • Price CAGR 33.35%
  • ROIC 14.3%
  • P/FCF 6.81
  • Operating Margin 20.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 50.6%
  • Analyst Consensus 85% Buy
  • Earnings Surprise avg 20.9%
  • PEG Ratio 0.28
  • Earnings Quality (OCF/NI) 1.26
  • Net Margin Trend 14.6% vs 11.6%
  • Piotroski F-Score 5/9

Fallido (8)

  • P/B Ratio 4.42
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue Growth 5Y 3.9%
  • Share Dilution 23.0%

No disponible (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

1.26

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

23.0%

Emitiendo nuevas acciones, diluyendo la participación

Participaciones institucionales

Gobernanza

Equipo Directivo

NombreCargoEdad
Dr. Saumya Sutaria M.D.Chairman & CEO52
Mr. Sun K. ParkExecutive VP & CFO49
Ms. Lisa Y. FooExecutive VP & Chief Operating Officer34
Ms. Paola M. ArbourExecutive VP & Chief Information Officer61
Mr. Thomas W. ArnstEVP, Chief Administrative Officer, Chief Risk Officer, General Counsel & Corporate Secretary62
Mr. John Michael GroomsSenior VP, Controller & Principal Accounting Officer47
Mr. William McDowell IIIVice President of Investor Relations-
Ms. Jana DurfeeSenior VP & Chief Compliance Officer-
Mr. Michael T. MaloneyExecutive Vice President of Corporate Development-
Mr. Clint HaileyChief Managed Care Officer & Senior VP60

Riesgo de Auditoría

4

Riesgo del Consejo

3

Riesgo de Compensación

2

Riesgo de Derechos del Accionista

1

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Documentos

  • Informe anual (10-K)

    Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

    Presentado el 2026-02-17

    Ver documento
  • Informe trimestral (10-Q)

    Una actualización del desempeño financiero de los últimos tres meses.

    Presentado el 2026-07-29

    Ver documento
  • Informe de hecho relevante (8-K)

    Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

    Presentado el 2026-09-22

    Ver documento

via SEC EDGAR

Historial de Resultados

via SEC EDGAR

Latest News

Recent headlines for THC, sourced from Markets Gazette.

  • 2/20/2026POSITIVE
    The Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts

    Recent analyst ratings for Tenet Healthcare (THC) show a predominantly positive sentiment, with multiple experts maintaining or reinstating "Buy" ratings. This suggests a favorable outlook for the stock, based on fundamental analysis or future growth prospects.

via Markets Gazette